Presentaties 2012

De medewerkers van SHM geven met regelmaat presentaties waarin bevindingen uit onderzoek en publicaties worden gepresenteerd. Een groot gedeelte van de presentaties is Engelstalig. Hieronder vindt u een overzicht van de presentaties in 2012.

  • Update on the HIV epidemic in the Netherlands
    Frank de Wolf
    Presentation
  • Pre-exposure prophylaxis amongst men who have sex with men in the netherlands
    Ard van Sighem
    Presentation
  • Changes in first-line cART regimens and clinical outcome between 1996 and 2010 in the Netherlands 
    Smit M, Smit C, Geerlings S, Gras L, Garnett G, Hallett T, de Wolf F. 
  • HIV-1 transmission networks on Curaçao, a Caribbean Island
    Daniela Bezemer
    Poster    
  • CD4 cell count changes following acute HCV infection in chronically HIV infected patients
    Luuk Gras
    Poster
  • Long-term CD4 cell count improvement in HIV-1 infected individuals with long-term sustained viral suppression on combination antiretroviral therapy
    Luuk Gras
    Poster
  • Response to anti-HCV treatment in HIV-infected patients chronically infected with Hepatitis C, the NVHB-SHM Hepatitis working group
    Colette Smit
    Poster
  • Decreased incidence of Pneumocystis jirovecii pneumonia among sub-Saharan African patients in the Dutch ATHENA cohort; genetic susceptibility or environmental factors? 
    Schoffelen A, van Lelyveld S, Barth R, Gras L, de Wolf F, Netea M, Hoepelman A.
  • An overview of the Dutch pediatric vertically HIV-infected population in the era of cART 
    Cohen S, Smit C, Pajkrt D, for the Dutch Pediatric HIV Study Group (PHON).

http://www.nchiv.org/

  • When to switch cART: Novel methods for the comparison of switching strategies using observational data 
    Cain LE, Sterne JAC, May MT, Ingle SM, Abgrall S, Saag MS and Hernán MA on behalf of the HIV-CAUSAL Collaboration and the ART-CC.
  • Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA 
    Grint D, Mocroft A, Vogel M, Beniowski M, Pradier C, Battegay M, Jevtovic D, Soriano V, Lundgren JD, Rockstroh JK, Kirk O an Peters L for EuroSIDA in EuroCOORD.
  • Computational models that predict response to HIV therapy may reduce virological failure and therapy costs in resource-limited settings 
    Revell AD, Wang D, Alvarez-Uria G, Streinu-Cercel A, Ene L, Wensing AMJ, Hamers RL, Morrow C, Robin WOOD, Tempelman H, De Wolf F, Nelson M, Montaner JS, Lane HC12, Larder BA on behalf of the RDI study group.
  • CD4 count and viral load specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use 
    Mocroft A, Phillips A, Gatell J, Horban A, Ledergerber B, Zilmer K, Jevtovic D, Maltez F, Kirk O, Lundgren J et al for the EuroSIDA study in EuroCoord.
  • Increases in acute hepatitis C (HCV) incidence across Europe: which regions and patient groups are affected? 
    Rockstroh JK, Grint D, Boesecke C, Soriano V, Lundgren JD, d’Arminio Monforte A, Mitsura VM, Kirk O, Mocroft A and Peters L for EuroSIDA in EuroCoord.
  • Immuno-virological discordance (ID) is associated with a higher frequency of fatal and non-fatal AIDS and non-AIDS 
    Zoufaly A, Cozzi-Lepri A, Kirk O, Lundgren JD, Reiss P, Jetovic D, Machala L, Zangerle R, Mocroft A, van Lunzen J on behalf of EuroSIDA in EuroCoord.
  • Advanced chronic kidney disease, endstage renal disease and renal death in HIV-positive individuals in Europe 
    Ryom L, Kirk O, Lundgren JD, Pedersen C, Reiss P, De Wit S, Buzunova S, Gasiorowski J, Gatell JM and Mocroft A on behalf of EuroSIDA in EuroCoord.
  • Impact of antiretroviral therapy (ART), viraemia and immunosuppression on lipid levels: the D:A:D Study 
    Kamara DA, Sabin C, Reiss P, Rickenbach M, Smith C, De Wit S, Law M, Mocroft A, Pradier C, Lundgren JD.

http://www.hiv11.com/

  • General overview of main approaches for estimating people living with HIV 
    Van Sighem A.
  • Use of longitudinal case reporting data for estimation HIV prevalence 
    Van Sighem A.

http://www.who.int/en/

  • Comorbidity and ageing in HIV-1 infection: the AGEhIV Cohort Study 
    Schouten J, Wit FW, Stolte IG, van der Valk M, Geerlings SE, de Wolf F, Prins M, Reiss P, on behalf of the AGEhIV Cohort Study Group.
  • Characteristics of individuals presenting late for care across Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) 
    Jens D Lundgren on behalf of the late presenters working group of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord.
  • Non-AIDS defining malignancies (NADM) and immunosuppression: The D:A:D study 
    Worm SW, Bower M, Reiss P, Grulich A, Fontas E, Bonnet F, Faetkenheuer G, Law M, Phillips A, Furrer HJ, El-Sadr W, Kirk O, Ryom L, Abrams D, D’Arminio Monforte A, De Wit S, Sabin C, Lundgren JD on behalf of the D:A:D study group.
  • Trends over time in underlying causes of death in the D:A:D Study from 1999 to 2011 
    Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, Kowalska J, Friis-Møller N, Phillips AN, Sabin CA, Lundgren JD for the D:A:D Study Group.

http://www.aids2012.org/

  • HBV and HCV in HIV-infected patients in care 
    Smit C. 
  • Effectiviteit HIV-testbeleid 
    Van Sighem A.

http://rivm.nl/English

  • Does (early) cART have a public health benefit?
    Frank de Wolf
    Presentation

http://www.stateofthecart.nl/home.html

  • Limited contribution to new infections from HIV-infected men who have sex with men on suppressive antiretroviral therapy
    Ard van Sighem
    Presentation

http://www.cfenet.ubc.ca/TasPConference

  • Higher rates of AIDS and death during the first year of therapy among those born outside Europe, the United States, and Canada: the importance of tuberculosis 
    Shepherd BE, Jenkins CA and Sterling on behalf of ART-CC.
  • Effect of hepatitis C treatment on the risk of death in HIV/HCV co-infected patients; European Cohort Collaboration (COHERE) in EuroCoord.
    Colette Smit (presenter), on behalf of the HCV working group of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord
  • Mortality after starting antiretroviral therapy (ART) in treatment-naïve adults in three continents: collaborative analysis of IeDEA and ART-CC cohorts 
    Boulle A, Schomaker M, Gsponder T, May M, Ingle S, Egger M and Sterne J for the IeDEA-SA and ART-CC cohort collaborations.
  • When to switch cART: Novel methods for the comparison of switching strategies using observational data 
    Cain LE, Sterne JAC, May MT, Ingle SM, Abgrall S, Saag MS and Hernán MA on behalf of the HIV-CAUSAL Collaboration and the ART-CC.
  • Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA 
    Grint D, Mocroft A, Vogel M, Beniowski M, Pradier C, Battegay M, Jevtovic D, Soriano V, Lundgren JD, Rockstroh JK, Kirk O an Peters L for EuroSIDA in EuroCOORD.
  • Emulating randomized trials with dynamic strategies: an empirical comparison between effect estimates from randomized and observational studies 
    Young JG, Cain LE and Hernán MA on behalf of the HIV-CAUSAL Collaboration.
  • Comorbidity and Ageing in HIV-1 infection 
    Schouten J, Wit FM, Stolte IG, van der Valk M, Geerlings SE, de Wolf F, Prins M, Reiss P, on behalf of the AGEhIV Study Group.
  • Advanced Renal Disease and End-Stage Renal Disease in Europe 
    Ryom L, Kik O, Kundgren JD, Pedersen C, Reiss P, de Wit S, Kutsyna G, Gasiorowski J, Gatell J and Mocroft M on behalf of EuroSIDA in EuroCOORD.
  • CD4 cell count changes following acute HCV infection in chronically HIV infected patients. 
    Luuk Gras (presenter), Colette Smit, Maria Prins, Frank de Wolf, Janke Schinkel, Femke Lambers, Joost van Hommerig, Jan van der Meer, Ronald Geskus and the ATHENA national observational HIV cohort
    Poster
  • Delayed entry into care after HIV diagnosis in Curacao.
    Gonneke Hermanides (presenter), Ard van Sighem, Cai Winkel, Izzy Gerstenbluth, Frank de Wolf, Ashley Duits
    Poster
  • Temporal trends in late presenters across the European continent 
    Reekie J, Mocroft A, Raben D, Lundgren J, and Kirk O on behalf of COHERE in EuroCoord.
  • Underreporting of TB-HIV co-infection in the national TB surveillance register in the Netherlands: a capture-recapture analysis 
    Van Leth F, Wit F, Kalisvaart N, Hillebregt M. Verbon A, Verhagen M, Sprenger H, Kiers A and Cobelens F.
  • History of injection drug use (IDU) and Hepatitis C as risk factors for mortality in the ART-CC 
    May M. Birnie K, Justice A, Hogg B, Ingle S, Sterne JAC on behalf of the Antiretroviral Therapy Cohort Collaboration (ART-CC).
  • Associations of risk group, gender and age with specific causes of death in the ART-CC 
    Ingle S, Gill J, Mugavero M, Lewden C, Abgrall S, Fätkenheuer G, Reiss P, May M, Sterne JAC and Saag M for the Antiretroviral Therapy Cohort Collaboration (ART-CC).
  • Fasting and non-fasting cholesterol and risk of myocardial infarction (MI): The D:A:D Study Group 
    Kamara DA, Worm SW, Sabin CA, Smith CJ, Philips A and Lundgren JD for the D:A:D Study Group.
  • Association of duration of HIV-infection, immunodeficiency and use of cART with the risk of severe chronic liver disease 
    Kesselring A, Wit F, Smit C, van der Valk M, Richter C, Reiss P and de Wolf F. 
  • Low CD4 in recently-infected individuals and the proportion experiencing rapid progression 
    Olson A on behalf of the CASCADE Collaboration in EuroCOORD.
  • HIV-1 transmission networks in Curacao. 
    Daniela Bezemer (presenter)

http://iwhod.org/

  • Estimating HIV prevalence in European countries
    Ard van Sighem (presenter)
    Presentation 

http://www.hiveurope.eu/

  • Non-AIDS defining malignancies (NADM) and immunosuppression: The D:A:D study 
    Worm SW, Bower M, Reiss P, Grulich A, Fontas E, Bonnet F, Faetkenheuer G, Law M, Phillips A, Furrer HJ, El-Sadr W, Kirk O, Ryom L, Abrams D, D'Arminio Monforte A, De Wit S, Sabin C, Lundgren JD on behalf of the D:A:D study group.
  • Evolution of HIV-1 Set-Point Viral Load within Transmission Networks 
    Daniela Bezemer (presenter), Luuk Gras, Ard van Sighem, Ben Berkhout, Christophe Fraser, Frank de Wolf  
    Poster 
  • Risk of HIV viremia depends on length of prior suppression <50 copies/ml and is increased in sub Sahara African patients living in the Netherlands
    Luuk Gras (presenter), Colette Smit, Marijn de Bruin, Daniela Bezemer, Jan Prins, Frank de Wolf, and the ATHENA national observational cohort
    Poster
  • Distribution of age at death and degree of immunosuppression vary according to cause of death in people with HIV-1 
    Gill J, Ingle S, Mugavero M, Lewden C, Abgrall S, Fätkenheuer G, Reiss P, May M, Sterne J, and Saag M for the Antiretroviral Therapy Cohort Collaboration (ART-CC).
  • Cumulative incidence of and risk factors for changes to first ART regimen and death prior to a change: the Antiretroviral Therapy Cohort Collaboration (ART-CC) 
    Abgrall S, Ingle S, Saag M, Cavassini M, Hogg R, Crane H, May M, Sterne J, and the Antiretroviral Therapy Cohort Collaboration (ART-CC).
  • Proportion of HIV Elite Controllers and Loss of Elite Status According to 2 Commonly Used Definitions 
    Olson A, Meyer L, Prins M, Thiebaut R, Guiguet M, Chaix M-L, Amornkul P, Babiker A, Porter K, and CASCADE Collaboration in EuroCoord.
  • Identification of Severe Primary HIV Infection through Clinical, Immunological and Virological Definitions 
    Lodi S, Fisher M, Phillips A, De Luca A, Ghosn J, Malyuta R, Zangerle R, Moreno S, Porter K, and CASCADE Collaboration in EuroCoord.
  • Exposure to Antiretrovirals (ARVs) and the Risk of Renal Impairment among HIV+ Persons with Normal Baseline Renal Function: the D:A:D Study 
    Ryom L, Mocroft A, Worm SW, Kamara DA, Reiss P, Ross M, Fux C, Morlat P, Moranne O, Smith C, Kirk O and Lundgren JD on behalf of the D:A:D study group.
  • Atazanavir (ATV)-Containing Antiretroviral Treatment is not Associated with an Increased Risk of Cardio- or Cerebro-Vascular Events (CVE) in the D:A:D Study 
    d’Arminio Monforte A, Reiss P, Ryom L, El-Sadr W, Dabis F, De Wit S, Worm SW, Phillips A, Lundgren J, and Sabin C.
  • Associations between Markers of Immunosuppression and the Risk of Cardiovascular Disease (CVD): the D:A:D Study 
    Sabin C, Worm SW, Law M, El-Sadr W, Reiss P, Bruyand M, Fontas E, d’Arminio Monforte A, Weber R, Kirk O, de Wit S, Lundgren JD on behalf of the D:A:D Study Group.

http://retroconference.org/

  • Tenofovir/emtricitabine versus abacavir/lamivudine
    Rebecca Holman (presenter), Luuk Gras, Jan Prins en Frank de Wolf
    Presentation

http://www.nvhb.nl/